SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as investors anticipate upcoming earnings, with discussions centering on the company's potential to capitalize on the AI automation trend. The community is weighing the possibility of a breakout, pointing to strong fundamentals and partnerships, while also acknowledging the stock's historical volatility and the need for positive guidance. Some are hoping for a meme-stock rally, while others focus on long-term growth.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as discussions around metaverse spending cuts fuel optimism and a potential shift in focus. Community members are pointing to positive technical indicators and discussing potential price movements, with some highlighting the impact of AI initiatives. Overall sentiment seems bullish, with many anticipating further gains.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

Polyrizon ($PLRZ) is trending due to promising results for its intranasal naloxone hydrogel, sparking significant after-hours momentum. The community is actively discussing the potential for a short squeeze reminiscent of other Israeli momentum stocks, while some traders are wary of potential dilution. With a low float, the stock is exhibiting high volatility, leading to speculation about potential price targets and comparisons to past high-flying stocks.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending following its earnings report, with initial positive reactions tempered by concerns about future performance and AI disruption; the community is actively debating whether the company's growth justifies its valuation and if its AI strategy is strong enough. Some investors express skepticism, citing a lack of trust in leadership and concerns about the company's ability to adapt to the evolving tech landscape, while others remain optimistic about its long-term potential.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending due to a mix of reactions to its latest earnings report and a new partnership with Palantir, with community discussions focusing on forward guidance and AI integration. Despite some initial concerns about revenue growth, several brokerages have raised their price targets, citing the company's growing AI ecosystem. The partnership with Palantir is also a key talking point, with investors speculating on the potential enterprise opportunities it could unlock.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth ($USAR) is trending due to a newly announced supply agreement between its subsidiary, Less Common Metals, and Solvay and Arnold Magnetic Technologies to supply rare earth metals. The community is discussing the significance of this agreement for rare earth independence and potential government support, while also debating the stock's volatility and comparing it to competitors.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending amid speculation about a potential Fed rate cut in December, fueled by dovish comments from Fed officials and recent economic data. Community members are debating whether this rally is sustainable or if it's a bull trap before a deeper correction, with some pointing to oversold conditions in tech and potential rotation into value stocks. Discussions also involve the impact of economic data, upcoming announcements, and technical analysis on the ETF's price movement.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors discuss its expansion into Canada and the potential impact on revenue, along with its recent acquisition of YourBio Health. Community members are debating whether these developments will drive the stock price higher or if it will face continued pressure from short sellers. Some see the company as undervalued, while others express concern about its ability to break through resistance levels.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to FDA feedback regarding its Huntington's disease gene therapy, with the agency indicating that Phase I/II data is unlikely to be sufficient for approval. The community is actively discussing the implications of this decision, including potential delays and the need for further clinical trials, alongside skepticism towards management. Some traders are weighing the long-term potential against the immediate regulatory challenges, with a few hoping for a reversal or buyout.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai ($AI) is trending amid discussions around government contracts and a potential shift away from competitors. The community is weighing the company's growth prospects against concerns about revenue and profitability, while some anticipate a short squeeze. Speculation about a possible acquisition is also circulating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. It operates through the following geographical segments: Japan and China. The Japan segment deals with licensing, preclinical studies, clinical trials, and sales. The China segment covers the integrated bio-pharma operations consisting of validation, preclinical trials, formulation, phase I to III clinical trials, manufacturing and sales. The company was founded on November 20, 2001 and is headquartered in Tokyo, Japan.

Current Price	$15.95
Prev Close	$12.02
Open	$15.95
Dividend Yield	0.00%
50-Day Moving Average	$15.01
Beta	0.00
Avg. Volume	0.00
PE Ratio	-162.92

52-Week High	$21.81
52-Week Low	$12.02
Market Capitalization	$886.8M
EPS (Annual)	$0.145
Price to Book	2.62
Revenue Per Employee	$179,767.11
Enterprise Value/EBITDA	N/A

GNIIF
GNI Group Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GNIIF News

GNIIFGNI Group Ltd.